66 related articles for article (PubMed ID: 9413856)
1. In vitro binding of MX2 (KRN8602) and epirubicin to human plasma protein.
Zhang WZ; Cosolo W; Zalcberg J
Pharmacology; 1997 Dec; 55(6):279-84. PubMed ID: 9413856
[TBL] [Abstract][Full Text] [Related]
2. An investigation of the cytotoxicity of the morpholino anthracycline MX2 against glioma cells in vitro.
Park SJ; Kaye AH; Hill JS
J Clin Neurosci; 2000 Jan; 7(1):42-7. PubMed ID: 10847650
[TBL] [Abstract][Full Text] [Related]
3. [Binding of epirubicin to human plasma protein and erythrocytes: interaction with the cytoprotective amifostine].
Pernkopf I; Tesch G; Dempe K; Kletzl H; Schüller J; Czejka M
Pharmazie; 1996 Nov; 51(11):897-901. PubMed ID: 9036391
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacokinetics of MX2, a new morpholino anthracycline, in CSF following intravenous injection].
Yamamoto H; Arita N; Ohnishi T; Hiraga S; Izumoto S; Taki T; Higuchi M; Hayakawa T; Shinkai H
Gan To Kagaku Ryoho; 1993 Jul; 20(9):1227-30. PubMed ID: 8333749
[TBL] [Abstract][Full Text] [Related]
5. Contradistinction between doxorubicin and epirubicin: in-vitro interaction with blood components.
Ramanathan-Girish S; Boroujerdi M
J Pharm Pharmacol; 2001 Jun; 53(6):815-21. PubMed ID: 11428657
[TBL] [Abstract][Full Text] [Related]
6. Effect of filgrastim on the pharmacokinetics of MX2 hydrochloride in patients with advanced malignant disease.
Morgan DJ; Hill JS; Clarke K; Stylli SS; Park SJ; Cebon J; Basser RL; Kaye AH; Geldard H; Maher DW; Green MD
Cancer Chemother Pharmacol; 1998; 41(5):423-6. PubMed ID: 9523740
[TBL] [Abstract][Full Text] [Related]
7. Induction of MDR1 gene expression by anthracycline analogues in a human drug resistant leukaemia cell line.
Hu XF; Slater A; Rischin D; Kantharidis P; Parkin JD; Zalcberg J
Br J Cancer; 1999 Feb; 79(5-6):831-7. PubMed ID: 10070877
[TBL] [Abstract][Full Text] [Related]
8. Cellular pharmacology of MX2, a new morpholino anthracycline, in human pleiotropic drug-resistant cells.
Watanabe M; Komeshima N; Naito M; Isoe T; Otake N; Tsuruo T
Cancer Res; 1991 Jan; 51(1):157-61. PubMed ID: 1988080
[TBL] [Abstract][Full Text] [Related]
9. [Antitumor effect of a new anthracycline derivative, MX2, against human glioma cells].
Kuratsu J; Mihara Y; Kochi M; Takaki S; Ushio Y
Gan To Kagaku Ryoho; 1989 Mar; 16(3 Pt 1):399-403. PubMed ID: 2930204
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of MX2 hydrochloride in patients with advanced malignant disease.
Morgan DJ; Hill JS; Clarke K; Stylli SS; Park SJ; Cebon J; Basser RL; Kaye AH; Geldard H; Maher DW; Green MD
Cancer Chemother Pharmacol; 1997; 40(3):202-8. PubMed ID: 9219502
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of KRN8602, 3'-deamino-3'-morpholino-13-deoxo-10-hydroxycarminomycin hydrochloride, MX2 x HCl in patients with metastatic breast cancer.
Katsumata N; Watanabe T; Tominaga T; Ogawa M; Adachi I; Enomoto K; Kajiwara T; Kusama M; Yamada Y; Abe O
Cancer Chemother Pharmacol; 1999; 43(6):441-4. PubMed ID: 10321502
[TBL] [Abstract][Full Text] [Related]
12. [Distribution and acute toxicity of a new morpholinoanthracycline, MX2, in normal rat brain after intra-arterial injection].
Izumoto S; Arita N; Hayakawa T; Ohnishi T; Hiraga S; Taki T; Yamamoto H
Gan To Kagaku Ryoho; 1991 Mar; 18(3):371-5. PubMed ID: 2003739
[TBL] [Abstract][Full Text] [Related]
13. MX2; 3'-deamino-3'-morpholino-13-deoxy-10-hydroxycarminomycin (KRN8602) in refractory metastatic breast cancer: results of a preliminary phase II trial.
Watanabe T; Narabayashi M; Haga S; Yamada Y; Kawamura E; Enomoto K; Kusama M; Kimura K; Adachi I; Abe O
Jpn J Clin Oncol; 1993 Aug; 23(4):246-9. PubMed ID: 8411738
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacokinetics and antitumor activity of MX2, a new morpholino anthracycline in brain tumor intracerebral transplanted in rats].
Kiya K; Ogasawara H; Fujita H; Sugiyama K; Kurisu K; Kawamoto K; Uozumi T; Shinkai H
Gan To Kagaku Ryoho; 1993 Apr; 20(5):631-5. PubMed ID: 8470921
[TBL] [Abstract][Full Text] [Related]
15. Subcellular localization and cellular pharmacokinetics of MX2, a new morpholino anthracycline in glioma cells using confocal laser scanning microscopy.
Kabuto M; Kubota T; Kobayashi H; Nakagawa T; Arai Y; Kitai R
Neurol Res; 1994 Aug; 16(4):257-64. PubMed ID: 7984256
[TBL] [Abstract][Full Text] [Related]
16. Activity of the morpholino anthracycline 3'-deamino-3'-morpholino-13-deoxo-10-hydroxycarminomycin (MX2) against human tumor colony-forming units in vitro.
Ebrahim el-Zayat AA; Izquierdo MA; Clark GM; Von Hoff DD
Invest New Drugs; 1995; 13(2):125-131. PubMed ID: 8617574
[TBL] [Abstract][Full Text] [Related]
17. [Phase II study of KRN8602 (MX2) for malignant lymphoma].
Okabe K; Sampi K; Kuraishi Y; Takemoto Y; Tamura K; Ogawa M
Gan To Kagaku Ryoho; 1998 Jun; 25(7):1001-6. PubMed ID: 9644314
[TBL] [Abstract][Full Text] [Related]
18. MX2, a morpholino anthracycline, as a new antitumor agent against drug-sensitive and multidrug-resistant human and murine tumor cells.
Watanabe M; Komeshima N; Nakajima S; Tsuruo T
Cancer Res; 1988 Dec; 48(23):6653-7. PubMed ID: 3180075
[TBL] [Abstract][Full Text] [Related]
19. [Combination effect of hyperthermia and MX2 on cultured glioma cell lines].
Mizumatsu S; Ono Y; Tamiya T; Matsumoto K; Ohmoto T; Furuta T
Gan To Kagaku Ryoho; 1999 May; 26(6):789-95. PubMed ID: 10410148
[TBL] [Abstract][Full Text] [Related]
20. [Antitumor effect of MX2, a new morpholino anthracycline against C6 glioma cells and its combination effect with photodynamic therapy in vitro].
Kabuto M; Kubota T; Kobayashi H; Nakagawa T; Kitai R; Uno H; Kodera T
No To Shinkei; 1995 Oct; 47(10):969-73. PubMed ID: 7577142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
